On May 19, 2025, Armata Pharmaceuticals (ARMP, Financial) saw its price target raised by HC Wainwright & Co. The new price target is now set at $9.00, up from the previous target of $7.00. This adjustment represents a 28.57% increase, reflecting the analyst's confidence in the company's performance.
The analyst responsible for this update, Joseph Pantginis, has maintained a "Buy" rating for Armata Pharmaceuticals (ARMP, Financial). This consistent rating underscores a positive outlook for the company's future prospects. The changes in the price target come as investors keep a close watch on Armata Pharmaceuticals' developments in the biopharmaceutical sector.
Armata Pharmaceuticals (ARMP, Financial) is listed on the AMEX exchange and continues to attract attention with its potential in the market. Investors and stakeholders will be closely monitoring any further updates from HC Wainwright & Co. as well as other analysts following the stock's performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Armata Pharmaceuticals Inc (ARMP, Financial) is $7.00 with a high estimate of $7.00 and a low estimate of $7.00. The average target implies an upside of 286.53% from the current price of $1.81. More detailed estimate data can be found on the Armata Pharmaceuticals Inc (ARMP) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Armata Pharmaceuticals Inc's (ARMP, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
